ArticleNature communications2020
The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 142 citations in OpenAlex.
- Effects of elevated serum urate on cardiometabolic and kidney function markers in a randomised clinical trial of inosine supplementation.Scientific reports · 2022Trial
- 6'‑O‑Caffeoylarbutin attenuates experimental hyperuricemia by regulating renal and intestinal urate transport, intestinal barrier integrity, and gut microbiota.Molecular medicine reports · 2026Article
- A Post-NGP Mitsuokella jalaludinii as a Therapeutic Candidate for Gout.MicrobiologyOpen · 2026Article
- Dietary Nucleotides as Potential Modulators of Inflammatory and Metabolic Pathways with Implications for Insulin Resistance.International journal of molecular sciences · 2026Review
- ABCG2 transporter: Structural and functional associations with gout (Review).International journal of molecular medicine · 2026Review
- Article
- Per- and polyfluoroalkyl substances and kidney disease: Genetic associations and computational prioritization of candidate toxicogenomic pathways.PLoS computational biology · 2026Article
- FKBP8 connects the Hsp70-Hsp90 chaperone machinery to the folding of membrane proteins.Nature communications · 2026Article
- Insights into the therapeutic strategies for aging and aging-associated diseases.Signal transduction and targeted therapy · 2026Review
- Response to Allopurinol and Febuxostat According to the Fractional Excretion of Urate in Men With Gout.Arthritis care & research · 2026Article
- Metabolic and inflammatory mechanisms in uric acid-induced tubular dysfunction: Emerging perspectives.Clinics (Sao Paulo, Brazil) · 2026Article
- ABCG2 Genetic Variability in Drug Exposure and Toxicity: Implications for Clinical Practice.Toxics · 2026Review
- Longitudinal Examination of the UA/HDL-C Ratio as a Biomarker for Fatty Liver Disease: Findings from a Five-Year Follow-Up. Genetics of Atherosclerotic Disease (GEA) Study.Diagnostics (Basel, Switzerland) · 2026Article
- Association of ABCG2 gene variants with urate levels in Mexican patients with type 2 diabetes and chronic kidney disease.Scientific reports · 2026Article
- Establishment of a novel cynomolgus monkey model of hyperuricemia.Animal models and experimental medicine · 2026Article
- Multi-omics and molecular testing: A new insight into the genetic mechanisms of sarcopenia and arthritis.Clinical and experimental medicine · 2026Article
- Gut microbiota Lactobacillus johnsonii alleviates hyperuricemia by modulating intestinal urate and gut microbiota-derived butyrate.Chinese medical journal · 2026Article
- A reductive uric acid degradation pathway in anaerobic bacteria.Life metabolism · 2025Article
- Molecular interplay between TXNIP and GLUT9 underlies uric acid transport dysregulation in vitro under hyperuricemic stress.European journal of medical research · 2025Article
- Association of the ABCG2 Q141K variant with gout in Kinh Vietnamese: a cross-sectional study.Clinical rheumatology · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
The pathophysiological nature of the common ABCG2 gout and hyperuricemia associated variant Q141K (rs2231142) remains undefined. Here, we use a human interventional cohort study (ACTRN12615001302549) to understand the physiological role of ABCG2 and find that participants with the Q141K ABCG2 variant display elevated serum urate, unaltered FEUA, and significant evidence of reduced extra-renal urate excretion. We explore mechanisms by generating a mouse model of the orthologous Q140K Abcg2 variant and find male mice have significant hyperuricemia and metabolic alterations, but only subtle alterations of renal urate excretion and ABCG2 abundance. By contrast, these mice display a severe defect in ABCG2 abundance and function in the intestinal tract. These results suggest a tissue specific pathobiology of the Q141K variant, support an important role for ABCG2 in urate excretion in both the human kidney and intestinal tract, and provide insight into the importance of intestinal urate excretion for serum urate homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.